These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 19946890)

  • 1. Measurement of QALYS and the welfare implications of survivor consumption and leisure forgone.
    Nyman JA
    Health Econ; 2011 Jan; 20(1):56-67. PubMed ID: 19946890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Welfare, QALYs, and costs - a comment.
    Liljas B
    Health Econ; 2011 Jan; 20(1):68-72. PubMed ID: 21157833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should the consumption of survivors be included as a cost in cost-utility analysis?
    Nyman JA
    Health Econ; 2004 May; 13(5):417-27. PubMed ID: 15127422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the welfare theoretic foundation of cost-effectiveness analysis-the case when survival is not affected.
    Liljas B
    Eur J Health Econ; 2010 Feb; 11(1):5-13. PubMed ID: 19255794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In defence of societal sovereignty: a comment on Nyman 'the inclusion of survivor consumption in CUA'.
    Richardson JR; Olsen JA
    Health Econ; 2006 Mar; 15(3):311-3; discussion 319-22. PubMed ID: 16389655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On future non-medical costs in economic evaluations.
    Liljas B; Karlsson GS; Stålhammar NO
    Health Econ; 2008 May; 17(5):579-91. PubMed ID: 17787027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-utility analysis of chronic spinal pain treatment outcomes: converting SF-36 data into quality-adjusted life years.
    Hatten AL; Gatchel RJ; Polatin PB; Stowell AW
    Clin J Pain; 2006 Oct; 22(8):700-11. PubMed ID: 16988566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [QALYS or not QALYS: that is the question?].
    Moatti JP; Auquier P; Le Coroller AG; Macquart-Moulin G
    Rev Epidemiol Sante Publique; 1995 Dec; 43(6):573-83. PubMed ID: 8552855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Not all "quality-adjusted life years" are equal.
    Marra CA; Marion SA; Guh DP; Najafzadeh M; Wolfe F; Esdaile JM; Clarke AE; Gignac MA; Anis AH
    J Clin Epidemiol; 2007 Jun; 60(6):616-24. PubMed ID: 17493521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
    Roe RH; Lass JH; Brown GC; Brown MM
    Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating feelings related to the uncertainty about future health in utility measurement.
    Gandjour A
    Health Econ; 2008 Oct; 17(10):1207-13. PubMed ID: 18074407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility analysis of cataract surgery in the second eye.
    Busbee BG; Brown MM; Brown GC; Sharma S
    Ophthalmology; 2003 Dec; 110(12):2310-7. PubMed ID: 14644712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longevity bias in cost-effectiveness analysis.
    Liu L; Rettenmaier AJ; Saving TR
    Health Econ; 2008 Apr; 17(4):523-34. PubMed ID: 17990284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-effectiveness analysis of two rehabilitation support services for women with breast cancer.
    Gordon LG; Scuffham P; Battistutta D; Graves N; Tweeddale M; Newman B
    Breast Cancer Res Treat; 2005 Nov; 94(2):123-33. PubMed ID: 16261411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-social welfare functions: a reply to Hansen et al.
    Edlin R
    J Health Econ; 2004 Sep; 23(5):899-905. PubMed ID: 15353185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
    Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
    Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Problems and solutions in calculating quality-adjusted life years (QALYs).
    Prieto L; Sacristán JA
    Health Qual Life Outcomes; 2003 Dec; 1():80. PubMed ID: 14687421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery.
    Gupta OP; Brown GC; Brown MM
    Am J Ophthalmol; 2008 May; 145(5):923-8. PubMed ID: 18329000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.